Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Cash & Equivalents: 2017-2025

Historic Cash & Equivalents for Dianthus Therapeutics (DNTH) over the last 8 years, with Sep 2025 value amounting to $56.0 million.

  • Dianthus Therapeutics' Cash & Equivalents rose 66.27% to $56.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.0 million, marking a year-over-year increase of 66.27%. This contributed to the annual value of $22.8 million for FY2024, which is 82.78% down from last year.
  • Latest data reveals that Dianthus Therapeutics reported Cash & Equivalents of $56.0 million as of Q3 2025, which was up 322.94% from $13.2 million recorded in Q2 2025.
  • In the past 5 years, Dianthus Therapeutics' Cash & Equivalents registered a high of $329.7 million during Q1 2024, and its lowest value of $10.1 million during Q1 2025.
  • Over the past 3 years, Dianthus Therapeutics' median Cash & Equivalents value was $40.3 million (recorded in 2023), while the average stood at $103.0 million.
  • In the last 5 years, Dianthus Therapeutics' Cash & Equivalents soared by 1,320.49% in 2024 and then crashed by 96.93% in 2025.
  • Over the past 4 years, Dianthus Therapeutics' Cash & Equivalents (Quarterly) stood at $15.4 million in 2022, then spiked by 761.21% to $132.3 million in 2023, then slumped by 82.78% to $22.8 million in 2024, then soared by 66.27% to $56.0 million in 2025.
  • Its Cash & Equivalents stands at $56.0 million for Q3 2025, versus $13.2 million for Q2 2025 and $10.1 million for Q1 2025.